Martin J. Madden

CIK: 0001696864

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (20.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (80.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

NVCR

NovoCure Ltd

Director

MBOT

Microbot Medical Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

NVCR
NovoCure Ltd
Jun 3, 2026
Award(A)
Direct
11.6K shares-
MBOT
Microbot Medical Inc.
Apr 1, 2026
Award(A)
Stock Option (Right to Buy)
Direct
10K shares-
NVCR
NovoCure Ltd
Jun 4, 2025
Award(A)
Stock Option (Right to Buy)
Direct
33.4K shares-
NVCR
NovoCure Ltd
Jun 3, 2025
Sale(S)
Direct
999 shares at avg. $17.19$17K
MBOT
Microbot Medical Inc.
Jan 28, 2025
Award(A)
Stock Option (Right to Buy)
Direct
10K shares-

		Type	Shares	Price		Ownership
Jun 3, 2026	NVCR NovoCure Ltd	Award(A)	11,610	-	$0	Direct
Apr 1, 2026	MBOT Microbot Medical Inc.	Award(A) Stock Option (Right to Buy)	10,000	-	-	Direct
Jun 4, 2025	NVCR NovoCure Ltd	Award(A) Stock Option (Right to Buy)	33,393	-	-	Direct
Jun 3, 2025	NVCR NovoCure Ltd	Sale(S)	999	$17.19	$17,176	Direct
Jan 28, 2025	MBOT Microbot Medical Inc.	Award(A) Stock Option (Right to Buy)	10,000	-	-	Direct

1-5 of 5 transactions

About Madden Martin J.

Madden Martin J. (SEC CIK 0001696864) files insider reports with the SEC as Director of NovoCure Ltd (NVCR) and Director of Microbot Medical Inc. (MBOT).

Signal8 holds 5 ownership filings by Madden Martin J., all Form 4s, filed between Jan 30, 2025 and Jun 5, 2026. Those filings report 5 transactions, from Jan 28, 2025 to Jun 3, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Madden Martin J.'s filings is in WAYNE, PA.

Recent filings by Madden Martin J.

Jun 3, 2026: Grant or award of NVCR shares (Form 4, code A).
Apr 1, 2026: Grant or award of MBOT derivative securities (Form 4, code A).
Jun 4, 2025: Grant or award of NVCR derivative securities (Form 4, code A).
Jun 3, 2025: Open-market sale of NVCR shares (Form 4, code S).
Jan 28, 2025: Grant or award of MBOT derivative securities (Form 4, code A).

Other insiders filing for NovoCure Ltd (NVCR)

Puri Michal Nath, Chief Human Resources Officer
Leonard Frank X, Chief Executive Officer
Ben Arye Barak, General Counsel
Danziger Asaf, Director
LEUNG GABRIEL, Director
Stafford Kristin, Director

How to read Form 4 transaction codes